| Diabetes Mellitus, Non-Insulin-Dependent
Atorvaliq vs Farxiga
Side-by-side clinical, coverage, and cost comparison for diabetes mellitus, non-insulin-dependent.Deep comparison between: Atorvaliq vs Farxiga with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsFarxiga has a higher rate of injection site reactions vs Atorvaliq based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Farxiga but not Atorvaliq, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Atorvaliq
Farxiga
At A Glance
Oral
Daily
HMG-CoA reductase inhibitor
Oral
Once daily
SGLT2 inhibitor
Indications
- Coronary heart disease
- Diabetes Mellitus, Non-Insulin-Dependent
- Heart failure
- Hyperlipidemia
- Hypercholesterolemia, Familial
- Hypertriglyceridemia
- Chronic Kidney Diseases
- Heart failure
- Diabetes Mellitus, Non-Insulin-Dependent
Dosing
Coronary heart disease, Diabetes Mellitus Non-Insulin-Dependent, Heart failure, Hyperlipidemia, Hypertriglyceridemia 10 or 20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily; patients requiring LDL-C reduction >45% may start at 40 mg once daily.
Hypercholesterolemia, Familial (HeFH, pediatric >= 10 years) 10 mg once daily orally on an empty stomach; dosage range 10-20 mg once daily.
Hypercholesterolemia, Familial (HoFH, pediatric >= 10 years) 10-20 mg once daily orally on an empty stomach; dosage range 10-80 mg once daily.
Chronic Kidney Diseases, Heart failure 10 mg orally once daily.
Diabetes Mellitus, Non-Insulin-Dependent Starting dose 5 mg orally once daily; may be increased to 10 mg orally once daily for additional glycemic control. Not recommended when eGFR is less than 45 mL/min/1.73 m2 for glycemic control.
Contraindications
- Acute liver failure or decompensated cirrhosis
- Hypersensitivity to atorvastatin or any excipients in ATORVALIQ
- Previous serious hypersensitivity reaction to dapagliflozin or any excipient in FARXIGA
Adverse Reactions
Most common (>=2%) Nasopharyngitis, arthralgia, diarrhea, pain in extremity, urinary tract infection, dyspepsia, nausea, musculoskeletal pain, muscle spasms, myalgia, insomnia, pharyngolaryngeal pain
Serious Myopathy, rhabdomyolysis, immune-mediated necrotizing myopathy, hepatic dysfunction, increases in HbA1c and fasting serum glucose
Postmarketing Pancreatitis, fatigue, fatal and non-fatal hepatic failure, anaphylaxis, tendon rupture, rhabdomyolysis, myositis, dizziness, peripheral neuropathy, cognitive impairment, depression, interstitial lung disease, angioneurotic edema, bullous rashes
Most common (>=2%) Female genital mycotic infections, nasopharyngitis, urinary tract infections, back pain, increased urination, male genital mycotic infections, nausea, influenza, dyslipidemia, constipation, discomfort with urination, pain in extremity
Serious Diabetic ketoacidosis, volume depletion, urosepsis and pyelonephritis, hypoglycemia with concomitant insulin or insulin secretagogues, necrotizing fasciitis of the perineum (Fournier's Gangrene), hypersensitivity reactions including anaphylaxis and angioedema
Postmarketing Necrotizing fasciitis of the perineum (Fournier's Gangrene), urosepsis and pyelonephritis, ketoacidosis, acute kidney injury, rash
Pharmacology
Atorvastatin is a selective, competitive inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts HMG-CoA to mevalonate, a cholesterol precursor; it lowers plasma cholesterol and LDL levels by inhibiting hepatic cholesterol synthesis and increasing hepatic LDL receptor expression.
SGLT2 inhibitor; dapagliflozin inhibits sodium-glucose cotransporter 2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion, while also reducing sodium reabsorption to lower cardiac pre- and afterload, suppress sympathetic activity, and decrease intraglomerular pressure via tubuloglomerular feedback.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
No coverage data available for Atorvaliq.
Farxiga
- Covered on 5 commercial plans
- PA (9/12) · Step Therapy (9/12) · Qty limit (11/12)
UnitedHealthcare
No coverage data available for Atorvaliq.
Farxiga
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (4/8)
Humana
No coverage data available for Atorvaliq.
Farxiga
- Covered on 0 commercial plans
- PA (1/3) · Step Therapy (1/3) · Qty limit (3/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
No savings programs available for Atorvaliq.
Cost estimate not availableAccessia Health: Heart Failure - Private Insurance
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Compare Other Drugs
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
AtorvaliqView full Atorvaliq profile
FarxigaView full Farxiga profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.